Literature DB >> 24395844

Reality check for pemetrexed and maintenance therapy in advanced non-small-cell lung cancer.

Nevin Murray1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24395844     DOI： 10.1200/JCO.2013.53.3448

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  MicroRNA-148b inhibits proliferation and the epithelial-mesenchymal transition and increases radiosensitivity in non-small cell lung carcinomas by regulating ROCK1.

Authors:  Haitao Luo; Caixia Liang
Journal:  Exp Ther Med       Date:  2018-02-07       Impact factor: 2.447

2.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Authors:  Gregory A Masters; Sarah Temin; Christopher G Azzoli; Giuseppe Giaccone; Sherman Baker; Julie R Brahmer; Peter M Ellis; Ajeet Gajra; Nancy Rackear; Joan H Schiller; Thomas J Smith; John R Strawn; David Trent; David H Johnson
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

3.  Expression of miR-148/152 family as potential biomarkers in non-small-cell lung cancer.

Authors:  Li Li; Ye-ye Chen; Shan-qing Li; Cheng Huang; Ying-zhi Qin
Journal:  Med Sci Monit       Date:  2015-04-23

4.  Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.

Authors:  Courtney Davis; Huseyin Naci; Evrim Gurpinar; Elita Poplavska; Ashlyn Pinto; Ajay Aggarwal
Journal:  BMJ       Date:  2017-10-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.